Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer is a research paper published in European Journal of Medicinal Chemistry (2022). On theSindex it has a DataRank of 0. It has been cited 33 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: T32 CA121938
National Institutes of Health
Grant: CA160911
National Institutes of Health
Grant: CA238042
National Institutes of Health
Grant: CA100768
NCI NIH HHS
Grant: R01 CA100768
NCI NIH HHS
Grant: R01 CA160911
FWCI
2.61
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
BindingDB Entry 50019933: Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.
Additional file 1 of NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation
Additional file 1 of NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation